Biovie Inc Market Cap ($14.62 Million)
Market Cap & Net Worth: Biovie Inc (BIVI)
Biovie Inc market cap. Biovie Inc (NASDAQ:BIVI) has a market capitalization of $14.62 Million ($14.62 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #25906 globally and #5453 in its home market, demonstrating a 30.08% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Biovie Inc's stock price $1.73 by its total outstanding shares 8451148 (8.45 Million). Also see cash efficiency ratio of Biovie Inc for how efficiently the company converts equity into cash flow.
Biovie Inc Market Cap History (2015–2026)
Biovie Inc market cap history from 2015 to 2026. Data shows change from $1.27 Billion to $14.62 Million (-33.51% CAGR). Check Biovie Inc (BIVI) share price today for real-time trading data and today's change.
Index Memberships
Biovie Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #722 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #2371 of 3165 |
Weight: Biovie Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Biovie Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Biovie Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore how fast is Biovie Inc growing its equity to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of BIVI by Market Capitalization
Companies near Biovie Inc in the global market cap rankings as of November 5, 2026. Also see Biovie Inc balance sheet assets for a full breakdown of the balance sheet.
Key companies related to Biovie Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Biovie Inc (2015–2026)
Market capitalization of Biovie Inc from 2015 to today. Between 2015 and today, Biovie Inc's market cap moved from $1.27 Billion to $ 14.62 Million, with a yearly change of -33.51%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $14.62 Million | +49.14% |
| 2025 | $9.80 Million | -42.00% |
| 2024 | $16.90 Million | -84.13% |
| 2023 | $106.48 Million | -83.78% |
| 2022 | $656.65 Million | +72.67% |
| 2021 | $380.30 Million | -74.02% |
| 2020 | $1.46 Billion | +394.86% |
| 2019 | $295.79 Million | -0.36% |
| 2018 | $296.85 Million | -81.27% |
| 2017 | $1.58 Billion | -49.15% |
| 2016 | $3.12 Billion | +145.83% |
| 2015 | $1.27 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Biovie Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $14.62 Million USD |
| MoneyControl | $14.62 Million USD |
| MarketWatch | $14.62 Million USD |
| marketcap.company | $14.62 Million USD |
| Reuters | $14.62 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Biovie Inc
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism. It also develops Be… Read more